Claims for Patent: 12,673,047
Summary for Patent: 12,673,047
| Title: | Compositions for the treatment of hypertension |
| Abstract: | Provided herein are pharmaceutical compositions that are useful for the treatment of hypertension comprising an angiotensin II receptor blocker, a diuretic, and a calcium channel blocker. |
| Inventor(s): | Anthony RODGERS, Stephen Macmahon |
| Assignee: | George Institute for Global Health |
| Application Number: | US19/341,633 |
| Patent Claims: |
1. A pharmaceutical composition for a treatment of hypertension, the pharmaceutical composition comprising: (a) telmisartan; (b) indapamide; and (c) amlodipine besylate, wherein a dose of the telmisartan is about 30 milligrams (mg) to about 50 mg, a dose of the indapamide is about 1.875 mg to about 3.125 mg, and a dose of the amlodipine besylate is about EQ 3.75 mg base to about EQ 6.25 mg base; and wherein the pharmaceutical composition is free of a beta blocker. 2. The pharmaceutical composition of claim 1, wherein the dose of the telmisartan is about 40 mg. 3. The pharmaceutical composition of claim 1, wherein the dose of the indapamide is about 2.5 mg. 4. The pharmaceutical composition of claim 1, wherein the dose of the amlodipine besylate is about EQ 5 mg base. 5. The pharmaceutical composition of claim 1, wherein the dose of the indapamide is about 2.5 mg and the dose of the amlodipine besylate is about EQ 5 mg base. 6. The pharmaceutical composition of claim 1, wherein the dose of the indapamide is about 2.5 mg and the dose of the telmisartan is about 40 mg. 7. The pharmaceutical composition of claim 1, wherein the dose of the amlodipine besylate is about EQ 5 mg base and the dose of the telmisartan is about 40 mg. 8. The pharmaceutical composition of claim 1, wherein the dose of the indapamide is about 2.5 mg, the dose of the amlodipine besylate is about EQ 5 mg base, and the dose of the telmisartan is about 40 mg. 9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is provided in the form of a pill or a tablet. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch